Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

BackgroundCyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherapy or as combination therapy with an aromatase inhi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sara M. Tolaney, Muralidhar Beeram, J. Thaddeus Beck, Alison Conlin, E. Claire Dees, Shannon L. Puhalla, Brent N. Rexer, Howard A. Burris, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N. Moore, Allison M. Manuel, Andrew Lithio, Gregory L. Price, Sonya C. Chapman, Lacey M. Litchfield, Matthew P. Goetz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-02-01
coleção:	Frontiers in Oncology
Assuntos:	abemaciclib metastatic breast cancer CDK4 CDK6 endocrine therapy
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2021.810023/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!